ESMO 2012 Conference
Vienna, Austria—Adding bevacizumab (Avastin) to chemotherapy improves outcomes in patients with platinum-resistant recurrent ovarian cancer, according to results of the phase 3 clinical trial AURELIA, which was presented at the 2012 European Society for Medical Oncology Congress. Bevacizumab improved progression-free survival (PFS) and overall response rate (ORR) with any of the 3 chemotherapy regimens in the study, but adding bevacizumab to weekly paclitaxel was the most active combination in an exploratory analysis of the trial.
Vienna, Austria—Costs associated with first-line pemetrexed/cisplatin are significantly lower than those of carboplatin/paclitaxel/bevacizumab for the treatment of advanced non–small-cell lung cancer (NSCLC), according to an analysis presented at the 2012 European Society for Medical Oncology Congress.
Vienna, Austria—In the first head-to-head phase 3 clinical trial, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (Xalkori) proved more effective than standard chemotherapy with pemetrexed (Alimta) or docetaxel (Taxotere) as a second-line treatment for patients with non–small-cell lung cancer (NSCLC) and the ALK genetic abnormality.
Updated Data Confirm Survival Benefits with T-DM1 in Breast Cancer and with Regorafenib in Colon Cancer
Vienna, Austria—The updated analyses of 2 major studies of drugs that were recently approved by the US Food and Drug Administration (FDA) confirm the benefits of trastuzumab emtansine (T-DM1) in patients with advanced HER2-positive breast cancer and of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC). Both studies were presented at the 2012 European Society for Medical Oncology (ESMO) Congress. Regorafenib was approved by the FDA for the treatment of mCRC during the ESMO meeting (see article here).
Vienna, Austria—Promising preliminary results for 2 novel prostate can-cer drugs—ODM-201 and OGX-427—were reported at the 2012 European Society for Medical Oncology Congress. Both drugs were studied for the treatment of castration-resistant prostate cancer (CRPC).
Vienna, Austria—A review of 34,000 patients with cancer in an insurance claims database showed that during the first 12 months after the diagnosis of cancer, the overall cost of developing venous thromboembolism (VTE) was approximately $100,000 per patient, reported Duke University researchers at the 2012 European Society for Medical Oncology.
Vienna, Austria—In a head-to-head comparison of 2 treatments for metastatic renal-cell carcinoma (mRCC), pazopanib (Votrient) showed similar efficacy to sunitinib (Sutent), with a 1-month survival advantage for sunitinib, which was associated with fewer side effects and an increased quality of life (QOL), suggested Robert J. Motzer, MD, Professor of Medicine, Weill Medical College of Cornell University, and an attending physician at Memorial Sloan-Kettering Cancer Center, New York.
Continuation of Bevacizumab Beyond Progression Improves Outcome in Patients with Metastatic Colorectal Cancer
Vienna, Austria—More support for the continuation of treatment with bevacizumab beyond disease progression in patients with metastatic colorectal cancer was reported at the 2012 European Society for Medical Oncology (ESMO) Congress, validating a small but growing body of previous data.
Results 1 - 8 of 8